Can a Triple-Action eye drop calm allergy itching and redness?
NCT ID NCT07805759
First seen Sep 04, 2026 · Last updated Sep 04, 2026
Summary
This trial tests whether Daydrop Triple Action eye drops can relieve symptoms of allergic conjunctivitis, such as itching, redness, and tearing. The drops contain ectoine, hyaluronic acid, and carboxymethylcellulose, which are meant to hydrate and protect the eye surface. About 49 adults with active allergic conjunctivitis will use the drops once or twice daily for 14 days. Researchers will measure changes in itching and redness, along with safety and patient satisfaction.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Daydrop Triple Action eye drops, containing ectoine, hyaluronic acid, and carboxymethylcellulose
- What this could lead to
- If it works, this could offer a non-drug option for people with allergic conjunctivitis to relieve itching, redness, and discomfort without relying on medicated drops.
- What could go wrong
- This is a small, early-stage study with no control group, so results may not be conclusive. The drops are not intended to treat the underlying allergy, only symptoms, and individual responses may vary.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 49 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2026
- Expected to finish
-
Sep 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adults aged 18 years or older * Active episode of allergic conjunctivitis prior to study initiation, assessed and confirmed by the specialist using a slit-lamp examination. * Score of ≥ 2 points on either the Ora Calibra Ocular Itching Score or the Ocular Redness Score, as assessed by the participant and the investigator, respectively. * Ability to self-administer the study product. * Ability to understand the Patient Information Sheet and provide written informed consent. Exclusion Criteria: * History of hypersensitivity to any component of the study product. * Systemic treatment with antihistamines (e.g., loratadine, cetirizine, desloratadine, ebastine) or corticosteroids (e.g., fluorometholone, loteprednol, dexamethasone), and/or topical treatment with any ophthalmic medication with anti-allergic or anti-inflammatory activity, including antihistamines or mast cell stabilizers (e.g., olopatadine, ketotifen, azelastine) and ophthalmic corticosteroids (e.g., fluorometholone, loteprednol, dexamethasone), except for artificial tears, within the week prior to study initiation. * Clinically significant ocular infection or inflammation. * Other active ocular conditions, including but not limited to glaucoma, Sjögren's syndrome, severe dry eye disease, Stevens-Johnson syndrome, active uveitis or keratitis, severe or chronic blepharitis, and other forms of conjunctivitis of non-allergic origin. * Ocular surgery within the 3 months prior to study entry. * Refractive surgery within the previous 6 months. * Pregnancy or planned breastfeeding.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Allergic conjunctivitis of both eyes are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Complutense Medical Center (Virtus Group)
RECRUITINGMadrid, Madrid, 28805, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.